Thrombosis Clinical Trial
Official title:
Extra Corporeal Life Support and Modification of Hemostasis
To evaluate change in coagulation tests during a 48-h period after initiation VV-ECMO and VA-ECMO. (ECMO= Extra Corporeal Membrane Oxygenator) Assessment of bleeding during Veno-Venous Extracoporeal Membrane Oxygenator (VV-ECMO) and Veno-Arterial Extracoporeal Membrane Oxygenator (VA-ECMO).
This is a multi-center, prospective, pilot cohort study, performed in the Intensive Care Units (ICUs) of the Ghent University Hospital, CHU Liège, University Hospital Brussels, and University Hospital Munster. Each group will contain 20 subjects; in total there will be 40 subjects 2 groups of 20 patients GROUP 1: VV-ECMO n = 20 GROUP 2: VA-ECMO n = 20 - Demographics: age, sex, comorbidities, medication, reason for ECMO therapy - Simplified Acute Physiology Score (SAPS) 3 at time of ICU admission. - Components of the Sequential Organ Failure Assessment score daily (based on worst value of each component of the score) - ECMO characteristics (place of cannulation, type of cannulas, oxygenator, bloodflow, gasflow and pressure registrations) - Incidence and severity of bleeding, scored according to the GUSTO and BARC scores - Coagulation profile: At inclusion (before heparine infusion is started), 2h after start of therapy, 24h, and 48h, and at specific moments of clinical suspicion of profound altered hemostasis. We defined a coagulation profile as a set of tests that includes - prothrombin time (PT), international normalized ratio (INR) - activated partial thromboplastin time (aPTT) and heparin ratio - the fibrinogen level - platelets - ACT (iACT®, …) - D-dimer - ROTEM (extem, intem, heptem) or TEG (Utrecht) - AT III - anti Xa - Temperature daily (H/L) (core) - Patient characteristics that may influence coagulation or the results of coagulation tests: body weight, Body Mass Index, drugs, C-reactive protein (as a marker for inflammation), Hemoglobin level, LDH, unconjugated bilirubin, (or haptoglobine or plasma free haemoglobin, if tested) - Heparin dose ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
| Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
| Completed |
NCT05426564 -
Exploratory Assessment of the Quantra® System in Adult ECMO Patients
|
||
| Not yet recruiting |
NCT05830916 -
Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
|
||
| Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
| Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
| Completed |
NCT02439190 -
CV004-007 Thrombosis Chamber Study
|
Phase 1 | |
| Completed |
NCT02526628 -
Thrombosis and Neurocognition in Klinefelter Syndrome
|
||
| Completed |
NCT02341638 -
Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01855516 -
Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin
|
N/A | |
| Unknown status |
NCT00983112 -
Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery
|
Phase 4 | |
| Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
| Completed |
NCT00346424 -
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
|
Phase 3 | |
| Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
| Completed |
NCT00143715 -
Oral Vitamin K for Warfarin Associated Coagulopathy
|
Phase 3 | |
| Terminated |
NCT00303420 -
Alteplase for Blood Flow Restoration in Hemodialysis Catheters
|
Phase 4 | |
| Completed |
NCT00039858 -
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
|
Phase 4 | |
| Completed |
NCT00007410 -
Genetic Architecture of Plasma T-PA and PAI-1
|
N/A | |
| Completed |
NCT00000538 -
Dietary Effects on Lipoproteins and Thrombogenic Activity
|
Phase 3 | |
| Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A |